Toripalimab Plus Chemotherapy for First-Line Advanced NSCLC
16412
post-template-default,single,single-post,postid-16412,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Toripalimab Plus Chemotherapy for First-Line Advanced NSCLC

Home > Blogs  > Toripalimab Plus Chemotherapy for First-Line Advanced NSCLC

29 Oct Toripalimab Plus Chemotherapy for First-Line Advanced NSCLC

Posted at 10:55h in Blogs by

In this Phase III study (CHOICE-01), patients with treatment-naive, advanced NSCLC with EGFR/ALK mutations, treatment with toripalimab (a humanized IgG4K monoclonal antibody specific for human PD-1) in combination with chemotherapy showed significantly better PFS (median PFS 13.1 v 5.5 months). This study supports the use of toripalimab in combination with chemotherapy as a front-line treatment option for patients with advanced NSCLC without EGFR/ALK driver mutations. (Ref: Wang Z et al. J Clin Oncol. Oct 7, 2022)

#oncologyresearch #clinicalresearch #clinicaldevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6992186328616472577/

 

No Comments

Sorry, the comment form is closed at this time.